GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians
- 1 December 2025
- journal article
- review article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (12) , 2228-2236
Abstract
No abstract availableKeywords
Funding Information
- Mayo Clinic
- Mayo Foundation for Medical Education and Research
This publication has 23 references indexed in Scilit:
- Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: systematic review and meta-analysisGastrointestinal Endoscopy, 2024
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2024
- Glucagon-like peptide-1 receptor agonists and capsule endoscopy in patients with diabetes: a matched cohort studyGastrointestinal Endoscopy, 2024
- AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: CommunicationClinical Gastroenterology and Hepatology, 2023
- Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022Journal of the American Pharmacists Association, 2023
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary DiseasesJAMA Internal Medicine, 2022
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 DiabetesJACC, 2020
- Glucagon‐like peptide‐1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2017
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trialsDiabetes, Obesity and Metabolism, 2016
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes MellitusJAMA Internal Medicine, 2013